RxDoctor Payments Data

Wendell McDaniel, DO

Family Medicine · Springtown, TXNPI 1508802646

Payments from drug & device makers

$1,692in general payments, 2019–2025

Across 75 payments — averaging $22.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$573
  • AstraZeneca$336
  • Novo Nordisk$185
  • GM Pharmaceuticals, Inc.$171
  • AbbVie$110
  • Lilly USA, LLC$87
  • plus $229 from 9 others

What the payments were for

  • Food & beverage$1,67299%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim33$573
AstraZeneca6$336
Novo Nordisk11$185
GM Pharmaceuticals, Inc.1$171
AbbVie(2 entities)6$110
Lilly USA, LLC6$87
Exact Sciences3$64
Abbott2$41
GSK1$21
Bayer1$20
Amgen1$19
Novartis1$18
Astellas Pharma US Inc1$18
Seqirus USA Inc1$17
Kowa Pharmaceuticals America, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,692 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$109,925
Medicare patients
185
Services billed
1,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin45$41,270
MounjaroTirzepatide15$23,803
EliquisApixaban12$16,960
TradjentaLinagliptin12$11,127
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,023
Spiriva RespimatTiotropium Bromide11$5,973
DilantinPhenytoin Sodium Extended12$2,462
Ezetimibe115$2,224
Atorvastatin Calcium303$2,011
Insulin Lispro Kwikpen U-100Insulin Lispro12$1,928
Albuterol Sulfate HfaAlbuterol Sulfate47$1,465
Fluticasone Propionate72$1,434
Losartan Potassium147$1,217
Rosuvastatin Calcium112$1,203
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl15$1,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$573$58,37068 claims
Lilly USA, LLCMounjaro$87$23,80315 claims
GSKTrelegy Ellipta$21$10,02312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Springtown

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →